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Transmissible spongiform encephalopathies (TSEs) may be acquired peripherally, in which case infectivity
usually accumulates in lymphoid tissues before dissemination to the nervous system. Studies of mouse scrapie
models have shown that mature follicular dendritic cells (FDCs), expressing the host prion protein (PrPc), are
critical for replication of infection in lymphoid tissues and subsequent neuroinvasion. Since FDCs require
lymphotoxin signals from B lymphocytes to maintain their differentiated state, blockade of this stimulation
with a lymphotoxin  receptor-immunoglobulin fusion protein (LTR-Ig) leads to their temporary dediffer-
entiation. Here, a single treatment with LTR-Ig before intraperitoneal scrapie inoculation blocked the early
accumulation of infectivity and disease-specific PrP (PrPSc) within the spleen and substantially reduced
disease susceptibility. These effects coincided with an absence of FDCs in the spleen for ca. 28 days after
treatment. Although the period of FDC dedifferentiation was extended to at least 49 days by consecutive
LTR-Ig treatments, this had little added protective benefit after injection with a moderate dose of scrapie. We
also demonstrate that mature FDCs are critical for the transmission of scrapie from the gastrointestinal tract.
Treatment with LTR-Ig before oral scrapie inoculation blocked PrPSc accumulation in Peyer’s patches and
mesenteric lymph nodes and prevented neuroinvasion. However, treatment 14 days after oral inoculation did
not affect survival time or susceptibility, suggesting that infectivity may have already spread to the peripheral
nervous system. Although manipulation of FDCs may offer a potential approach for early intervention in
peripherally acquired TSEs, these data suggest that the duration of the treatment window may vary widely
depending on the route of exposure.
The transmissible spongiform encephalopathies (TSEs) or
“prion diseases” are chronic neurodegenerative diseases that
affect humans and both wild and domestic animals. Most TSEs,
including natural sheep scrapie, bovine spongiform encepha-
lopathy (BSE), chronic wasting disease (CWD) in mule deer
and elk, and variant Creutzfeldt-Jakob disease (vCJD) in hu-
mans, are most likely transmitted by peripheral exposure. For
example, the emergence of vCJD in the United Kingdom pop-
ulation is almost certainly due to consumption of BSE-contam-
inated meat products (7, 25). After peripheral inoculation with
TSE agents, high levels of infectivity and the disease-specific
isoform of the host prion protein (5) (PrPSc) usually accumu-
late in lymphoid tissues prior to their detection in the central
nervous system (CNS). This accumulation in lymphoid tissues
appears critical for efficient neuroinvasion (19), suggesting an
important role for the immune system in the propagation of
infectivity from the periphery to the CNS.
Within the lymphoid tissues of patients with vCJD (24), most
sheep with natural scrapie (56), or after experimental periph-
eral inoculation of rodents with scrapie (6, 28, 37, 39, 44), early
PrPSc accumulation takes place in the germinal centre on fol-
licular dendritic cells (FDCs). Studies of mouse scrapie models
have shown that mature FDCs are critical for replication in
lymphoid tissues and, in their absence, neuroinvasion after
peripheral challenge is significantly impaired (6, 17, 31, 37–39,
46, 51). From the lymphoid tissues infectivity spreads to the
CNS via peripheral nerves (21).
Cytokines produced by B lymphocytes, such as lymphotoxins
(LTs), provide essential signals for FDC development and
maturation (10, 34). Studies from genetically immunodeficient
mice have shown that in the absence of LT (43) or LT (33)
the development of FDC networks is blocked. The membrane-
bound form of LT (LT12 heterotrimer) is expressed on
activated lymphocytes, and signaling is mediated through the
LT receptor (LTR) expressed on stromal cells such as FDCs
(12). Signaling via the LTR is likewise necessary for the
development of FDCs as they do not develop in mice deficient
in this receptor (20). In adult mice, the maintenance of preex-
isting FDC networks in a differentiated state also requires
continual stimulation through the LTR since they rapidly
collapse from their mature state when signaling is blocked by a
specific inhibitor of the LTR pathway (40).
We and others have previously shown that, in the temporary
absence of mature FDCs after treatment with LT receptor-
immunoglobulin fusion protein (LTR-Ig [16]), early scrapie
accumulation in the spleen is blocked and neuroinvasion is
significantly delayed (37, 46). Since these studies imply that
FDCs could be targeted for early therapeutic intervention
against TSE agents, further experiments were performed in the
current study to address the following questions. First, does
treatment with LTR-Ig reduce susceptibility to peripherally
inoculated scrapie and, if so, to what extent? Second, since the
effects of LTR-Ig on FDC status are temporary (22, 40), do
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consecutive doses of LTR-Ig prolong the period of FDC
dedifferentiation and, if so, does this further reduce disease
susceptibility? Finally, since early PrPSc accumulation occurs
upon FDCs after oral inoculation of rodents (3) and sheep (1,
23) with scrapie and of mule deer with CWD (54), are FDCs
important for TSE pathogenesis after oral inoculation? To
address this question, mice were treated with LTR-Ig before
or shortly after oral scrapie inoculation to determine whether
temporary FDC dedifferentiation reduced susceptibility to
orally inoculated scrapie and, if so, how long after inoculation
such intervention was possible?
MATERIALS AND METHODS
LTR-Ig treatment. C57BL mice (8 to 12 weeks old) were given a single
intraperitoneal (i.p.) injection of a fusion protein containing the soluble LTR
domain linked to the Fc portion of human immunoglobulin G1 (IgG1; LTR-Ig
[16]) or 100 g of polyclonal human IgG (hu-Ig; Sandoglobulin) as a control. In
some cases, mice were given one or two subsequent doses of 100 g of LTR-Ig
or 100 g of hu-Ig at 21-day intervals.
Scrapie infection. At the times indicated relative to treatment, mice were
injected i.p. with 20 l of a 1.0, 0.1, 0.01, or 0.001% (wt/vol) dilution of unspun
brain homogenate from C57BL mice terminally affected with ME7 scrapie (20 l
of a 1.0% homogenate represents a dose of ca. 104.5 intracerebral [i.c.] ID50 [50%
infectious dose] units). For oral inoculation, mice were fed individual food
pellets doused with 50 l of a 1.0% scrapie brain homogenate. After challenge,
animals were coded and evaluated weekly for signs of clinical disease and then
killed at a standard clinical endpoint (18). Scrapie diagnosis was confirmed by
histopathological assessment of vacuolation in the brain. Where indicated, some
mice were sacrificed 70 days postchallenge, and spleens, mesenteric lymph nodes
(MLNs), and Peyer’s patches were obtained for further analysis. For bioassay of
scrapie infectivity, individual half-spleens were prepared as 10% (wt/vol) homog-
enates in physiological saline, and 20-l portions were injected i.c. into groups of
12 C57BL indicator mice. The scrapie titer in each spleen was determined from
the mean incubation period in the assay mice by reference to established dose-
and incubation period-response curves for scrapie-infected spleen tissue (11).
Immunohistochemical analysis. To monitor the effects of treatment on FDC
status tissues were taken from two mice from each group at the times indicated
after treatment and snap-frozen at the temperature of liquid nitrogen. Frozen
sections (6 m) were cut on a cryostat, and FDCs visualized by staining with
FDC-specific rat monoclonal antiserum FDC-M1 (BD Pharmingen, San Diego,
Calif.) or FDC-M2 (AMS Biotechnology, Abingdon, United Kingdom) or 8C12
monoclonal antiserum to detect CD35 (BD Pharmingen). Complement compo-
nents were detected by using rat monoclonal antiserum RMC7H8 specific for
C1q (Connex, Martinsried, Germany) or RMC11H9 specific for C3 (Connex).
Immunolabeling was carried out by using alkaline phosphatase coupled to the
avidin-biotin complex (Vector Laboratories, Burlingame, Calif.). Vector Red
(Vector Laboratories) was used as a substrate.
For the detection of PrP in brain tissue and Peyer’s patches, tissues were fixed
in periodate-lysine-paraformaldehyde and embedded in paraffin wax. Sections (6
m) were deparaffinized and pretreated to enhance PrP immunostaining by
hydrated autoclaving (15 min, 121°C, hydration) and subsequent immersion in
formic acid (98%) for 5 min (44). Sections were then stained with the PrP-
specific polyclonal antiserum 1B3 (14) and immunolabeling was detected by
using hydrogen peroxidase coupled to the avidin-biotin complex (Vector Labo-
ratories) with diaminobenzidine as a substrate. Glial fibrillary acid protein
(GFAP) was detected on adjacent brain sections by using rabbit GFAP-specific
antiserum (Dako, Ltd., Ely, United Kingdom), and immunolabeling was carried
out by using alkaline phosphatase coupled to the avidin-biotin complex (Vector
Laboratories) with Vector Red as a substrate.
All sections were counterstained with hematoxylin to distinguish cell nuclei.
Immunoblot detection of PrPSc. Spleen fragments or MLNs (approximately
half the total from each mouse assayed) were prepared as previously described
(13, 36, 39). Briefly, before immunoblot analysis, tissue homogenates were
treated with 40 g of proteinase K (to confirm the presence of PrPSc) and
subsequently partially purified by treatment with 2% (wt/vol) N-lauroylsarcosine
(in 0.1 M Tris [pH 7.4]), allowing sedimentation only of the proteinase K-
resistant, detergent-insoluble fraction of PrP (PrPSc). Samples were subjected to
electrophoresis through sodium dodecyl sulfate–10 to 20% polyacrylamide gels
(Bio-Rad, Hemel Hempstead, United Kingdom) and then transferred to poly-
vinylidine difluoride membranes (Bio-Rad) by semidry blotting. PrP was de-
tected with the PrP-specific mouse monoclonal antiserum 8H4 (59), followed by
alkaline phosphatase-conjugated goat-anti mouse antiserum (Jackson Immu-
noresearch Laboratories, Inc., West Grove, Pa.), and bound alkaline phospha-
tase activity was detected with SigmaFast NBT/BCIP solution (Sigma, Poole,
Dorset, United Kingdom).
RESULTS
Effect of LTR-Ig treatment on FDC status. Temporary
blockade of the LTR signaling pathway was achieved by a
single i.p. injection of 100 g of LTR-Ig (16). After treatment
of mice with LTR-Ig, expression of the FDC markers FDC-
M1, FDC-M2, and CD35 (complement receptor 1) was unde-
tectable in the spleen 3 days (data not shown) and 7 days (Fig.
1) after treatment. FDCs characteristically trap and retain an-
tigens on their surfaces through interactions between comple-
ment components and cellular complement receptors (47, 50).
Here, the loss of expression of complement receptor 1 (Fig. 1)
in the spleens of LTR-Ig-treated mice coincided with a sub-
FIG. 1. Effect of LTR-Ig treatment on FDC status in spleens of
uninfected mice. Tissues were taken on the days indicated postinjec-
tion with hu-Ig (control) or LTR-Ig, and adjacent frozen sections
stained with FDC-M1 (top row; red) and FDC-M2 (second row; red)
monoclonal antiserum to detect FDCs, 8C12 monoclonal antiserum to
detect CD35 (third row; red), and monoclonal antiserum specific for
complement components C1q (fourth row; red) and C3 (lower row;
red). Expression of FDC-M1, FDC-M2, CD35, and associated accu-
mulations of complement components C1q and C3 were undetectable
in the spleen after treatment with LTR-Ig. Original magnification,
400.
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stantially decreased abundance of complement components
C1q and C3 (Fig. 1). The remaining complement-specific im-
munostaining is likely to represent macrophage-associated C1q
and C3 (15, 52). Taken together, these data imply that after
treatment with LTR-Ig the FDCs, if present, were dediffer-
entiated and had lost their ability to trap and retain antigens in
the germinal center. Although the effects of LTR-Ig treat-
ment on FDC status are temporary, little evidence of recov-
ered FDC networks was detected in the spleen 28 days after
treatment (Fig. 1). Treatment of mice with 100 g of poly-
clonal human IgG (hu-Ig) as a control had no adverse effect on
FDC status 7 days (Fig. 1) or 28 days (data not shown) after
injection.
Effect of LTR-Ig treatment on scrapie susceptibility. Mice
were given a single i.p. injection of LTR-Ig (or hu-Ig as a
control) 3 days before i.p. inoculation with a moderate or
limiting dose of scrapie. Treatment with LTR-Ig prior to
scrapie inoculation significantly reduced disease susceptibility
and extended survival time (Table 1). For example, after in-
jection with a moderate dose of scrapie (20 l of a 1.0%
scrapie brain homogenate), all control-treated mice suc-
cumbed to disease with a mean incubation period of 296  8
days (n  8), whereas five of seven mice treated with LTR-Ig
developed disease 45 days later, with a mean incubation period
of 341 22 days (Table 1). Two LTR-Ig-treated mice re-
mained free of signs of scrapie 500 days postinoculation. Char-
acteristic spongiform pathology, PrPSc accumulation, and re-
active astrocytes expressing high levels of GFAP were detected
in the brains of all LTR-Ig-treated and hu-Ig-treated control
animals which developed clinical signs of scrapie (data not
shown). In contrast, spongiform pathology, PrPSc accumula-
tion or reactive astrocytes were not detected in the brains of
the two surviving LTR-Ig-treated mice (data not shown).
When mice were inoculated with scrapie directly into the CNS
by intracerebral injection, treatment with LTR-Ig prior to
scrapie challenge had no effect on the incubation period of
disease or pathology within the brain compared to controls (37;
data not shown). This finding is consistent with the lack of
transfer of high-molecular-weight soluble receptors and IgG
through the blood-brain barrier (49).
Treatment of mice with LTR-Ig prior to i.p. inoculation
with lower doses of scrapie (20 l of a 0.1% or 0.01% scrapie
brain homogenate) demonstrated a striking effect on disease
susceptibility (Table 1). When mice were treated with hu-Ig 3
days before injection with a 0.1% scrapie brain homogenate, all
mice developed neurological disease with a mean incubation
period of 337 5 days (n 8; Table 1). In contrast, six of eight
mice treated with LTR-Ig remained free of the signs of
scrapie for at least 550 days after inoculation. Comparisons of
disease susceptibilities between mice treated with LTR-Ig
and hu-Ig suggest that blockade of the LTR-signaling path-
way reduced disease susceptibility approximately 100-fold.
Scrapie infectivity and PrPSc accumulation in the spleen.
Within 70 days of an i.p. injection of untreated mice with the
ME7 scrapie strain, high levels of infectivity and the disease-
specific isomer of the prion protein, PrPSc, accumulate within
lymphoid tissues (6, 13, 36, 39). In the present study, spleens
were taken from two control and two LTR-Ig-treated mice 70
days after i.p. injection with a moderate dose of scrapie (1.0%
scrapie brain homogenate) and halved. PrPSc accumulation
was determined in one half by immunoblot analysis, whereas
the scrapie infectivity titer in the other half was estimated by
bioassay in groups of 12 indicator mice. As expected, spleens
from control mice treated with hu-Ig 3 days before scrapie
challenge contained high levels of infectivity (ca. 5.7 log i.c.
ID50/g as estimated by incubation period assay; Fig. 2a) and
abundant detergent-insoluble, relatively proteinase-K-resistant
PrPSc (Fig. 2a, lanes 2 and 4). However, after treatment of
mice with LTR-Ig 3 days before scrapie challenge, no PrPSc
and only trace levels of infectivity were detected in the spleen
70 days postinoculation (Fig. 2a, lanes 6 and 8). This finding is
consistent with long-term persistence of a fraction of the in-
fectivity from the inoculum (17).
High levels of PrPSc accumulation were also detected at the
terminal stage of disease in the spleens of all hu-Ig-treated
control animals that developed clinical signs of scrapie (Fig. 2b,
lanes 2 and 4). The effects of LTR-Ig treatment on FDC
status are temporary, and mature networks begin to reappear
approximately 28 days after injection. Thus, the detection of
high levels of PrPSc in the spleen at the terminal stage of
disease of all LTR-Ig-treated animals that developed clinical
signs of scrapie is consistent with replication on the recovered
FDC networks (Fig. 2b, lanes 10 and 12). In contrast, PrPSc was
undetectable in the spleen of one mouse that remained free of
the signs of scrapie 500 days after inoculation, implying that
this mouse would have been unlikely to develop clinical disease
(Fig. 2b, lane 8). However, high levels of PrPSc were detected
in the spleen of the other mouse that was free of the signs of
scrapie 500 days after inoculation (Fig. 2b, lane 6). Although
characteristic signs of neurodegeneration and PrPSc accumu-
lation were not detected in the brain 500 days after inoculation
(data not shown), this mouse may have developed clinical
scrapie after a substantially prolonged incubation period.
Effect of multiple LTR-Ig treatment on scrapie suscepti-
bility. Since the effects of LTR-Ig treatment on FDC status
are temporary, we next sought to determine whether pro-
longed FDC dedifferentiation would further reduce suscepti-
bility to inoculation with a moderate dose of scrapie. To
achieve this, mice were given a single i.p. injection of 100 g of
LTR-Ig (or 100 g of hu-Ig as a control) 3 days before i.p.
inoculation with a 1.0% scrapie brain homogenate. After
TABLE 1. Effect of LTR-Ig treatment on susceptibility to i.p.-
inoculated scrapiea
%
Inoculum
dilution
(wt/vol)
hu-Ig LTR-Ig
Incidence Mean incubationperiod (days)  SE Incidence
Mean incubation
period (days)  SE
1.0 8/8 296  8 5/7 341  22, 2  500
0.1 8/8 337  5 2/8 322, 354, 6  550b
0.01 7/9 330  8, 2  550 0/7 7  550c
0.001 0/8 8  550 0/8 8  550d
a Incidence  number of animals affected/number of animals tested. The
notation “N   500” means that mice were free of the signs of scrapie up to at
least this time after inoculation.
b One mouse was killed 541 days after inoculation. No histopathological signs
of scrapie were detected in the brain (data not shown).
c One mouse was killed 386 days after inoculation. No histopathological signs
of scrapie were detected in the brain (data not shown).
d Three mice were killed 326, 371, and 515 days after inoculation. No his-
topathological signs of scrapie were detected in their brains (data not shown).
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scrapie challenge, mice were then given one or two subsequent
100-g doses of LTR-Ig or hu-Ig at a 21-day interval (day 21
and day 42 postinoculation with scrapie). The 21-day treatment
interval was chosen to prevent significant FDC recovery be-
tween treatments. To monitor the effects of multiple treat-
ments on FDC status, spleens were taken from two mice from
each group 7 days after the final treatment. Immunohisto-
chemical analysis demonstrated that treating mice with con-
secutive doses of LTR-Ig extended the duration of FDC
inactivation (Fig. 3). For example, when mice were given three
consecutive doses of LTR-Ig, the FDC markers FDC-M2 and
CD35 remained undetectable for up to at least 49 days after
the first treatment (Fig. 3). Likewise, the follicular localization
of complement components C1q and C3 was also significantly
diminished in the spleen (Fig. 3). Treatment of mice with
consecutive doses of hu-Ig (control) had little effect on FDC
status (Fig. 3).
In comparison to mice treated with consecutive doses of
hu-Ig as a control, treatment with two or three consecutive
doses of LTR-Ig significantly reduced disease susceptibility to
i.p. inoculation with a moderate dose of scrapie and extended
the survival time (Table 2). However, despite the prolonged
effects of treatment on FDC dedifferentiation, consecutive
doses of LTR-Ig had little extra benefit, in terms of suscep-
tibility or survival time, compared to mice given a single
LTR-Ig treatment (Table 2).
Effect of LTR-Ig treatment on scrapie pathogenesis after
oral inoculation. The effects of LTR-Ig treatment on FDC
status are not only confined to the spleen (40). As illustrated in
Fig. 4, FDCs in the Peyer’s patches and MLNs also temporarily
dedifferentiate within 3 days of treatment with LTR-Ig. Since
gut-associated lymphoid tissues have been implicated as po-
tential sites of TSE accumulation and neuroinvasion after oral
inoculation, we investigated the effects of temporary FDC in-
activation on disease susceptibility after ingestion. Mice were
given a single i.p. injection of LTR-Ig (or hu-Ig as a control)
3 days before or 14 days after oral inoculation with a moderate
dose of scrapie (mice were fed individual food pellets doused
FIG. 2. Treatment with LTR-Ig prior to i.p. scrapie inoculation
blocks the early accumulation of PrPSc and infectivity in the spleen.
Mice were treated with LTR-Ig or hu-Ig (as a control) 3 days before
i.p. scrapie inoculation, and tissues were assayed 70 days after inocu-
lation (a) or at the terminal stage of disease (b). Immunoblots show the
accumulation of detergent insoluble, relatively proteinase K (PK)-
resistant PrPSc. Treatment of tissue in the presence () or absence (	)
of proteinase K before electrophoresis is indicated. After proteinase K
treatment, a typical three-band pattern was observed between molec-
ular mass values of 20 and 30 kDa, representing unglycosylated, mono-
glycosylated, and diglycosylated isomers of PrP (in order of increasing
molecular mass). PrP was detected by using the PrP-specific monoclo-
nal antiserum 8H4. Lane M contained molecular mass markers. The
scrapie infectivity titer is expressed as the log i.c. ID50 units/g. (a) A
total of 1 of 12 assay mice developed clinical scrapie within 500 days of
inoculation; (b) 2 of 12 assay mice developed clinical scrapie within 500
days of inoculation. dpi, day postinoculation on which the tissues were
analyzed; pos., mice that developed clinical signs of scrapie; neg., mice
that were free of the clinical signs of scrapie.
FIG. 3. Effect of multiple hu-Ig or LTR-Ig treatments on FDC
status in spleen. Mice were given a single i.p. injection of 100 g of
LTR-Ig (or 100 g of hu-Ig as a control) 3 days before i.p. inoculation
with scrapie. After scrapie challenge, mice were then given one or two
subsequent doses of 100 g of LTR-Ig or 100 g of hu-Ig at 21-day
intervals (days 21 and 42 postinoculation with scrapie). Spleens were
taken from two mice from each group 7 days after the last treatment
(day 7, day 28, or day 49 after inoculation with scrapie for mice given
one, two or three consecutive treatments, respectively). Adjacent fro-
zen sections were stained with FDC-M2 monoclonal antiserum to
detect FDCs (top row; red), 8C12 monoclonal antiserum to detect
CD35 (second row; red), and monoclonal antisera specific for comple-
ment components C1q (third row; red) and C3 (fourth row; red). All
sections were counterstained with hematoxylin (blue). After treatment
of mice with three consecutive doses of LTR-Ig, the expression of
FDC-M2, CD35, and associated accumulations of complement com-
ponents C1q and C3 remained undetectable for up to at least 49 days
after the first treatment. Original magnification, 200.
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with 50 l of a 1.0% scrapie brain homogenate). Whereas all
mice treated with hu-Ig as a control 3 days before scrapie
inoculation succumbed to disease with a mean incubation pe-
riod of 342  6 days (n  8), treatment with LTR-Ig had a
dramatic affect on disease susceptibility. All mice given
LTR-Ig 3 days before inoculation remained free of the signs
of scrapie for at least 518 days postinoculation (Table 3). Char-
acteristic spongiform pathology, PrPSc accumulation, and re-
active astrocytes were detected in the brains of all hu-Ig-
treated control animals that developed clinical signs of scrapie
(Fig. 5). In contrast, no evidence of spongiform pathology,
PrPSc accumulation, or reactive astrocytes were detected in the
brains of any surviving LTR-Ig-treated mice assayed 518 days
postinoculation (Fig. 5).
When mice were treated with LTR-Ig 14 days after scrapie
inoculation, no significant effect on the survival time or disease
susceptibility was observed compared to control mice (Table
3). Furthermore, spongiform pathology, reactive astrocytes,
and PrPSc accumulation typical of an infection with the ME7
scrapie strain were detected in the brains of all mice treated
with hu-Ig or LTR-Ig that developed clinical disease (Fig. 5).
Effect of LTR-Ig treatment on PrPSc accumulation in Pey-
er’s patches, MLNs, and the spleen. Levels of disease-specific
PrP were determined in the Peyer’s patches, MLNs, and
spleens of mice treated with hu-Ig or LTR-Ig prior to or
shortly after oral inoculation with scrapie. Within 70 days of
oral inoculation, strong accumulations of disease-specific PrP
were found within the germinal centers of Peyer’s patches from
control mice treated with hu-Ig 3 days before inoculation (Fig.
6a). The cellular distribution of the PrP was consistent with
accumulation in association with FDCs (6, 44). After the early
onset of accumulation, high levels of disease-specific PrP were
sustained in Peyer’s patches of control-treated mice through to
the terminal stage of disease (data not shown). However, treat-
ment with LTR-Ig prior to inoculation blocked the accumu-
lation of disease-specific PrP within Peyer’s patches (Fig. 6b).
Within the Peyer’s patches of these LTR-Ig-treated mice,
only basal levels of staining typical of the cellular form of PrP
(PrPc) were detected in the germinal center (6). In contrast,
when mice were treated 14 days after inoculation, strong ac-
cumulations of disease-specific PrP were found within Peyer’s
patches from both control and LTR-Ig-treated mice (Fig. 6c
and d, respectively).
A similar pattern of disease-specific PrP distribution was
also detected in the MLNs. Within 70 days of inoculation,
strong accumulations of PrPSc were found within the MLNs
from control mice treated with hu-Ig 3 days before inoculation
(Fig. 6e, lanes 2 and 4). However, treatment with LTR-Ig
prior to inoculation blocked the accumulation of PrPSc within
MLNs assayed 70 days after inoculation (Fig. 6e, lanes 6 and
8). Consistent with the observations made in Peyer’s patches
(Fig. 6c and 6d), when mice were treated 14 days after inocu-
lation, strong accumulations of PrPSc were found within MLNs
from both control and LTR-Ig-treated mice when they were
analyzed 70 days after inoculation (Fig. 6f).
No PrPSc was detected in the spleens of any of the control or
LTR-Ig-treated mice assayed 70 days after inoculation (data
not shown). However, strong accumulations of PrPSc were
found at the terminal stage of disease in tissues from control
mice treated with hu-Ig 3 days before (Fig. 6g, lanes 2 and 4)
or 14 days after inoculation (Fig. 6 h, lanes 2 and 4). These data
suggest that after uptake from the gut lumen, PrPSc is propa-
gated from the Peyer’s patches to the MLNs via the lymphatics
and subsequently distributed to the spleen and other lymphoid
tissues, probably via the bloodstream. Consistent with the data
FIG. 4. Effect of LTR-Ig treatment on FDC status in Peyer’s
patches and MLNs. Tissues were obtained 3 days postinjection with
hu-Ig (control; upper panels) or LTR-Ig (lower panels), and sections
were stained with FDC-M2 monoclonal antiserum (red) to detect
FDCs. All sections were counterstained with hematoxylin (blue). Mature
FDC-M2-expressing FDCs were undetectable in Peyer’s patches and
MLNs after treatment with LTR-Ig. Original magnification, 200.
TABLE 2. Effect of multiple LTR-Ig treatments on
susceptibility to scrapiea
No. of
dosesb
hu-Ig LTR-Ig
Incidence Mean incubationperiod (days)  SE Incidence
Mean incubation period
(days)  SE
1 8/8 296 8 5/7 341  22, 2  500
2 8/8 305 7 5/8 351  12, 3  510c
3 9/9 312 13 7/9 369  26, 2  510d
a See Table 1, footnote a.
b Mice were given a single i.p. injection (100 g) of LTR-Ig or hu-Ig (as a
control) 3 days before i.p. inoculation with scrapie. Mice were then given injec-
tions of LTR-Ig or hu-Ig (100 g) at 21-days intervals after scrapie inoculation.
c One mouse was killed 414 days after inoculation. No histopathological signs
of scrapie were detected in the brain (data not shown).
d Two mice were killed 320 and 336 days after inoculation. No histopatholog-
ical signs of scrapie were detected in their brains (data not shown).
TABLE 3. Effect of LTR-Ig treatment on susceptibility to orally
inoculated scrapiea
Day of
treatmentb
hu-Ig LTR-Ig
Incidence Mean incubationperiod (days)  SE Incidence
Mean incubation
period (days)  SE
	3 8/8 342 6 0/7 7  518
14 8/8 351 12 9/9 356  3
a See Table 1, footnote a.
b Mice were given a single i.p. injection (100 g) of LTR-Ig or hu-Ig (as a
control) 3 days before (	3) or 14 days after (14) oral inoculation with scrapie.
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presented above (Fig. 6b and e), PrPSc accumulation in the
spleen was blocked after treatment with LTR-Ig prior to
inoculation since none was detected 518 days after inoculation
(Fig. 6g, lanes 6 and 8). Strong accumulations of PrPSc were
found within spleens from mice treated with LTR-Ig 14 days
after inoculation when measured at the terminal stage of dis-
ease (Fig. 6 h, lanes 6 and 8).
DISCUSSION
We have shown here that a single treatment of LTR-Ig
before i.p. injection with scrapie significantly extended the
survival time and reduced disease susceptibility approximately
100-fold compared to control treated mice. Our studies also
demonstrated that treatment prior to peripheral exposure
blocked the early accumulation of infectivity and disease-spe-
cific PrPSc within the spleen. These effects coincided with a
temporary dedifferentiation of mature FDCs in the spleen for
at least 28 days after treatment with LTR-Ig. Although it was
possible to extend the period of FDC dedifferentiation beyond
28 days by treating mice with consecutive doses of LTR-Ig,
prolonged FDC dedifferentiation had little extra effect on sus-
ceptibility to a moderate dose of scrapie compared to mice
given a single LTR-Ig treatment. We also demonstrate that
mature FDCs are critical for the transmission of scrapie from
the gut lumen to the CNS. In the present study, a single
treatment with LTR-Ig prior to oral scrapie inoculation
blocked the accumulation of PrPSc in the Peyer’s patches and
MLNs and prevented the development of CNS disease. How-
ever, treatment with LTR-Ig 14 days after oral inoculation
had no effect on survival time or susceptibility, suggesting in-
fectivity may have spread to the peripheral nervous system by
this time.
The effects of LTR-Ig treatment on FDC status are tem-
porary since the cells recover once the levels of LTR-Ig in
serum fall below a threshold level (22), but in our study there
was little evidence of FDC restoration 28 days after injection.
Antigens are trapped and retained on the surface of FDCs
through interactions between complement components and
cellular complement receptors (47, 50). The loss of expression
FIG. 5. Immunohistological analysis of brain tissue from mice treated with hu-Ig or LTR-Ig 3 days before (	3) or 14 days after (14) oral
inoculation with scrapie. Large disease-specific PrP accumulations (upper row; brown), reactive astrocytes expressing high levels of GFAP (middle
row; red), and spongiform pathology (H&E; lower row) were detected in the hippocampi of all mice showing clinical signs of scrapie. In contrast,
in the brains of mice treated with LTR-Ig 3 days before inoculation (LTR-Ig 	3), no evidence of PrP accumulation, reactive astrocytes, or
spongiform pathology was detected 518 days after inoculation. All sections were counterstained with hematoxylin (blue). dpi, day postinoculation
on which the tissues were analyzed; pos., mice that developed clinical signs of scrapie; neg., mice that were free of the clinical signs of scrapie.
Original magnification, 100.
6850 MABBOTT ET AL. J. VIROL.
of complement receptor 1 (CD35) and substantially decreased
abundance of complement components C1q and C3 in lym-
phoid follicles of treated mice indicated that the ability to
retain antigens in lymphoid follicles was significantly impaired.
Recent studies have identified the antigen recognized by the
FDC-specific antiserum FDC-M2 as complement component
C4 (55). Thus, the temporary loss of FDC-M2-specific immu-
nostaining after treatment with LTR-Ig is also consistent with
the inability of these cells to trap and retain complement-
opsonized antigens. Complement components C1q and C3 and
cellular complement receptors have been shown to play an
important role in the localization of scrapie infectivity to FDCs
(32, 36). Since PrPc expression is also eliminated in lymphoid
follicles after treatment with LTR-Ig (37, 46), these data
suggest the capability of FDCs, if present, to acquire and rep-
licate TSE infectivity would be temporarily abolished for at
least 28 days.
The fate of the FDCs after LTR-Ig treatment is not known,
but several mechanisms could be responsible either singularly
or in combination. First, FDCs could dedifferentiate to an
immature state that lacks their antigen-trapping characteris-
tics. Second, in the absence of LTR stimulation, FDCs may
undergo apoptosis. Studies are in progress to determine
whether immature FDC processes are detectable at the ultra-
structural level or whether there is significant evidence of ap-
optosis. Finally, since recovering FDCs appear in a more dif-
fuse pattern than the compact networks present in control
mice (22), it is possible that a LTR-dependent chemokine
gradient responsible for the localization of FDCs within the
germinal center is disturbed, resulting in their dispersal.
After i.p. inoculation of immunocompetent mice with the
ME7 scrapie strain, high levels of infectivity are present in the
spleen as soon as 35 days postinfection, reaching plateau levels
within 70 days postinfection (6, 13, 39). In the present study,
when mice were given LTR-Ig before scrapie challenge, no
PrPSc and only trace levels of infectivity were detected in the
spleen at 70 days postinfection, about 40 days after the ex-
pected reappearance of mature FDCs. These data are consis-
tent with the requirement for mature FDCs for scrapie repli-
cation in lymphoid tissues (6, 17, 31, 37, 39, 46). However,
immunoblot analysis of spleens from LTR-Ig-treated mice
that developed neurological disease after protracted incuba-
tion periods stained strongly for PrPSc. The most likely expla-
nation for these observations is that, in the absence of FDCs at
the time of scrapie challenge, trace amounts of infectivity from
the inoculum persist in the host in a cell or compartment that
is not affected by LTR blockade. Macrophages have been
proposed as candidate cells for TSE accumulation in the ab-
sence of FDCs (51). The extended survival time in LTR-
treated mice could simply be related to the time required for
FDC networks to restore and initiate replication of the inocula.
This would delay the subsequent transfer of infectivity via
peripheral nerves into the CNS (21). However, LTR treat-
ment also significantly reduced disease susceptibility, suggest-
ing a substantial portion of the inoculum is destroyed, for
example, by macrophages (4, 9). These data are congruent with
the suggestion that the action of macrophages on TSE patho-
genesis is dose dependent: small doses of infectivity may be
easily destroyed by macrophages, whereas higher doses are less
easily digested and a fraction is retained.
Although the effects of LTR-Ig treatment on scrapie
pathogenesis are consistent with an absence of mature FDCs at
the time of inoculation, our study does not entirely exclude the
possibility that other effects of LTR blockade also make a
contribution. For example, blockade of LTR signaling may
have impaired cell trafficking and the transport of infectivity
from the site of scrapie challenge to the spleen. Although the
direct involvement of migratory bone marrow-derived den-
dritic cells (DCs [a distinct lineage from FDCs]) in TSE patho-
genesis is not known, recent studies suggest that signaling via
LTR by the membrane LT12 heterotrimer is required for
their presence in lymphoid tissues (58). However, we have
previously demonstrated that LTR-Ig treatment significantly
FIG. 6. Treatment with LTR-Ig prior to oral scrapie inoculation
blocks the accumulation of disease-specific PrP in Peyer’s patches,
MLNs, and spleens. Mice were treated with LTR-Ig or hu-Ig as a
control 3 days before (a, b, e, and g; 	3) or 14 days after (c, d, f, and
h; 14) oral inoculation with scrapie. Disease-specific PrP accumula-
tions were determined in Peyer’s patches (a to d) and MLNs (e and f)
assayed 70 days after inoculation and in the spleen (g and h) at the
terminal stage of disease. In panels a to d, PrP accumulations in
Peyer’s patches were detected on paraffin-embedded sections with the
PrP-specific polyclonal antiserum 1B3 (PrP, red). Sections were coun-
terstained with hematoxylin (blue). Original magnification, 100. In
panels e to h, immunoblots show the accumulation of detergent-insol-
uble, relatively proteinase K (PK)-resistant PrPSc in the MLNs (e and
f) and spleens (g and h) of treated mice. Treatment of the tissue in the
presence () or absence (	) of proteinase K before electrophoresis is
indicated. PrP was detected by using the PrP-specific monoclonal an-
tiserum 8H4. Lane M contained molecular mass markers. dpi, day
postinoculation on which the tissues were analyzed; pos., mice that
developed clinical signs of scrapie; neg., mice that were free of the
clinical signs of scrapie.
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extends survival time when given as late as 42 days after scrapie
injection (37), making it unlikely that the effects of LTR
blockade on scrapie pathogenesis are due to impaired cell
trafficking.
Subsequent experiments were undertaken to determine
whether it was possible to further decrease susceptibility to a
moderate dose of scrapie by extending the period of FDC
dedifferentiation beyond 28 days. Our studies showed that
when mice were given three consecutive doses of LTR-Ig (at
21-day intervals) mature FDCs were undetectable up to at
least 49 days after the first treatment. However, despite the
prolonged effects of treatment on FDC dedifferentiation, treat-
ment with consecutive doses of LTR-Ig had little extra pro-
tective benefit compared to mice given a single treatment of
LTR-Ig. These data do not exclude the possibility that con-
secutive treatments with LTR-Ig would protect mice from
inoculation with a 10-fold-lower dose of scrapie (0.1% scrapie
brain homogenate) since only two of eight mice developed
clinical disease after a single LTR-Ig treatment (Table 1).
Montrasio et al. treated mice with 300 g of LTR-Ig prior to
scrapie inoculation, followed by seven further doses of 100 g
at weekly intervals (46). Despite the use of a significantly
greater amount of LTR-Ig over a longer time period than
that used in the present study, most mice eventually developed
clinical disease after i.p. scrapie inoculation (46). The effect of
the number or magnitude of the LTR-Ig doses was not de-
termined in that above study, but our data suggest that a single
low dose of LTR-Ig is almost as effective as two and even
three consecutive doses. Prolonged cytokine signaling block-
ade may cause serious side effects, including increased suscep-
tibility to other infectious microorganisms, increased incidence
of malignancies, or induction of autoimmune disease (35).
Therefore, if such an approach were ever to have practical use
against TSE diseases, treatment would ideally be administered
over a short duration to reduce complications from adverse
effects.
Although unexpected, these findings (Table 2) are in accor-
dance with studies that indicate that the reduced susceptibility
of some immunodeficient mice to TSE challenge can be over-
come in a proportion of mice by inoculation with a high dose
of infectivity. For example, severe combined immunodeficient
(SCID) mice and mice deficient in tumor necrosis factor alpha,
LT, LT, or LTR all lack mature FDCs in lymphoid tissues,
but a proportion develop disease after inoculation with a high
or moderate dose of scrapie (17, 31, 39, 42, 48, 51). In the
permanent absence of FDCs, a study by Prinz et al. (51) sug-
gests that macrophages are plausible candidates for scrapie
replication and neuroinvasion from lymphoid organs. How-
ever, neuroinvasion after inoculation with a high dose of
scrapie possibly also occurs after direct uptake of infectivity by
nerve terminals at the site of inoculation or after transport to
peripheral nerves by DCs (2).
The suggestion that consumption of BSE-contaminated
meat products is the most likely cause of vCJD in humans (7,
25) has focused attention on the gastrointestinal tract as an
important portal of TSE entry. Peyer’s patches are the primary
inductive sites in gut-associated lymphoid tissues that actively
acquire antigens from the lumen of the intestine. After intra-
gastric or oral inoculation of rodents with scrapie, infectivity
and PrPSc accumulate first in Peyer’s patches, gut-associated
lymphoid tissues, and ganglia of the enteric nervous system
long before their detection in the CNS (3, 30, 41, 45). Natural
sheep scrapie may also be acquired orally as PrPSc is detected
in Peyer’s patches and gut-associated lymphoid tissues (1)
prior to detection within the CNS (57). Within the gut-associ-
ated lymphoid tissues of orally inoculated rodents (3) or sheep
(1, 23) with scrapie and mule deer inoculated with CWD (54),
disease-specific PrP accumulations occur in association with
FDCs. In the present study, temporary FDC inactivation prior
to oral inoculation prevented the development of clinical dis-
ease and blocked the accumulation of PrPSc in Peyer’s patches
and MLNs. These data demonstrate that mature FDCs are
critical for the transmission of scrapie from the gut lumen to
the CNS and exclude the possibility of direct uptake of infec-
tivity from the gut lumen into PrPc-expressing enteric nerves
(53).
We have previously shown that temporary FDC inactivation
significantly extends survival time when treatment with
LTR-Ig is delayed for up to at least 42 days after i.p. scrapie
inoculation (37). Surprisingly, in the present study treatment
with LTR 14 days after oral inoculation with scrapie did not
significantly affect survival time or disease susceptibility. The
levels of infectivity responsible for natural TSE transmissions
are not known but are likely to be much lower than the mod-
erate dose used in the present study. Further studies will de-
termine whether treatment reduces susceptibility when given
14 days (or later) after oral inoculation with lower doses of
scrapie. In the Peyer’s patches and MLNs of immunocompe-
tent mice, replication of scrapie on FDCs is likely to have
already begun within 14 days of inoculation. Treatment with
LTR-Ig has no affect on disease pathogenesis once infection
is established within the CNS (37). The lack of any observable
effect of LTR-Ig treatment on disease pathogenesis when
given 14 days after oral inoculation is therefore consistent with
the hypothesis that neuroinvasion has already occurred. Re-
cent studies have demonstrated that PrPSc accumulates within
enteric ganglia soon after oral inoculation (3, 45). In the Pey-
er’s patch, FDC networks are situated distal from the gut
lumen and lie in close association with nerve fibres that run
along the gut wall (3). Therefore, it is plausible to suggest that
after accumulation and/or replication upon FDCs, neuroinva-
sion occurs rapidly and most likely via the enteric nerves in the
gut wall or Peyer’s patch adjacent to FDCs (3, 45). Our studies
do not exclude the possibility that infection also spreads to the
peripheral nervous system from the MLNs at a similar time
point, but the lack of detectable PrPSc in the spleen 70 days
after inoculation suggests the spleen does not play an early
role. Thus, these data illustrate that LTR-Ig may be used as
a tool in subsequent experiments to determine precisely the
onset of neuroinvasion after peripheral inoculation.
Treatments that inactivate FDCs may have therapeutic ap-
plication in some other pathological conditions. For example,
FDC inactivation may reduce the severity of some autoim-
mune diseases. Also, FDC-associated human immunodefi-
ciency virus particles comprise a major viral reservoir in in-
fected patients (8), and removal may improve the efficacy of
antiviral therapies. Moreover, the elimination of FDCs may
reduce the survival of some lymph node-resident lymphomas
that require FDCs for their survival (22, 29). Current evidence
suggests that the human TSE disease, vCJD, shares a similar
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requirement for FDCs in its pathogenesis, since PrPSc is asso-
ciated with FDCs in lymphoid tissues from infected patients
(24) and has been detected in the appendix prior to the onset
of clinical disease (26, 27). Thus, manipulation of FDCs may
offer a potential approach for early intervention in peripherally
acquired TSEs. However, treatments that specifically interfere
with the maturation of FDCs will only be effective during the
time interval between exposure to infection and spread of
disease to the peripheral nervous system. Although little is
known about the precise timing of these events, comparisons of
the effects of LTR-Ig treatment on scrapie pathogenesis
when inoculated via the peritoneal cavity (37) or gastrointes-
tinal tract (current study) suggest that these effects may vary
widely depending on the route of exposure. Therefore,
LTR-Ig may be used as a tool in future experiments to pre-
cisely determine the duration of FDC involvement in TSE
pathogenesis.
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